ArticleActa neuropathologica communications2026
α-Synuclein overexpression increases the tropism of pre-formed fibrils and MSA-patient derived seeds towards oligodendroglia.
Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple system atrophy (MSA) is a rare, fatal neurodegenerative disease, pathologically characterized by glial cytoplasmic inclusions (GCIs) containing α-synuclein (αSyn). The causes leading to aberrant αSyn accumulation in oligodendroglia remain unknown. Recent evidence of increased αSyn mRNA in GCI-bearing oligodendrocytes suggests that oligodendroglia αSyn expression may be a key determinant of GCI formation. To ascertain this, we generated a new transgenic (TG) mouse line overexpressing human (h-) αSyn through the myelin basic protein promoter (MBP-hSNCA mice). Immunofluorescence combined with machine learning-based classification confirmed age-independent oligodendroglial αSyn localization, with no evidence of aggregated and pathological αSyn, as assessed by a FRET-based assay, biochemical fractionation, and the seed amplification assay (SAA). Upon intrastriatal inoculation of hαSyn preformed fibrils (hPFFs), the fraction of oligodendroglial αSyn positive insoluble aggregates increased over time in TG compared to wildtype (WT) mice, reaching significance six to nine months after inoculation. This was accompanied by an increase in brain αSyn seeding potency. As proof of concept, we investigated whether preferential oligodendroglia vulnerability is influenced by intrinsic fibril potency by intrastriatally injecting TG and WT mice with αSyn fibrils amplified from 2 MSA or 1 PD patient's brains. Six months post inoculation, MSA-inoculated brains retained the MSA-characteristic seeding profile and exhibited higher seeding potency compared to PD-inoculated mice. TG mice showed significantly more widespread phosphorylated αSyn (pSyn) pathology than WT, independent of whether they were seeded with MSA- or PD-fibrils. However, oligodendroglial inclusions were significantly more abundant in TG mice injected with MSA-derived αSyn. In conclusion, our results indicate that intracellular αSyn expression facilitates the development of oligodendroglial pathology, supporting the hypothesis that increased αSyn expression may represent a rate-limiting step in GCI formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.